Managing antiphospholipid syndrome in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Immunology
• Rheumatology

Background:

• Antiphospholipid syndrome (APS) is an autoimmune disorder marked by antiphospholipid antibodies (aPL), leading to thrombosis and obstetric complications.
• Obstetric APS (OAPS) can cause recurrent pregnancy loss, fetal demise, and premature birth due to placental issues.
• Current management with aspirin and heparin improves outcomes in 70-80% of OAPS pregnancies, but limitations remain.

Purpose of the Study:

• This review focuses on the current treatment strategies for obstetric antiphospholipid syndrome (OAPS).
• To highlight the effectiveness and limitations of existing OAPS treatments.
• To discuss emerging therapeutic options for pregnant women with aPL.

Main Methods:

• Review of current literature on obstetric antiphospholipid syndrome (OAPS) management.
• Analysis of treatment outcomes and complications in pregnant women with APS.
• Exploration of retrospective data suggesting potential new therapies.

Main Results:

• Aspirin and heparin therapy leads to successful pregnancy outcomes in 70-80% of OAPS cases.
• Despite current care, 20-30% of APS pregnancies experience complications.
• Hydroxychloroquine and pravastatin show potential in retrospective studies for OAPS treatment.

Conclusions:

• While current treatments improve OAPS outcomes, they are not universally effective.
• Further research and clinical trials are needed for novel OAPS therapies.
• Exploring agents like hydroxychloroquine may offer improved management for pregnant women with aPL.